Antibody

50개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved50 programs
AntibodyCurated CoreFDAMerckApproved

pembrolizumab (Keytruda)

Multiple solid tumors · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1669Status Approved
AntibodyCurated CoreFDAJanssenApproved

daratumumab (Darzalex)

Multiple myeloma · CD38

#CD38#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 454Status Approved
AntibodyCurated CoreFDAJohnson & JohnsonApproved

teclistamab (Tecvayli, JNJ-64007957, teclistamab-cqyv)

Relapsed or refractory multiple myeloma · BCMA × CD3

#BCMACD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 132Status Approved
AntibodyCurated CoreFDARegeneronApproved

linvoseltamab (Lynozyfic, REGN5458, linvoseltamab-gcpt)

Relapsed or refractory multiple myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody · BCMA × CD3

#BCMACD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 24Status Approved
AntibodyCurated CorestaleRocheApproved

Tocilizumab (Tocilizumab)

Multiple Myeloma (MM); Multiple Myeloma Refractory · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Approved#BioJungboMoa-pick#Popular+5
Trials 161Status Recruiting
AntibodyLimited DatastaleGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 65Status Active
AntibodyCurated CorestaleGenentech, Inc.Phase 2

Ocrelizumab (Ocrelizumab)

Rheumatoid Arthritis · Multiple Sclerosis

#MultipleSclerosis#Antibody#Phase2#BioJungboMoa-pick#Popular+4
Trials 58Status Discontinued
AntibodyLimited DatastalePfizerPhase 3

Elotuzumab (Elotuzumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 57Status Recruiting
AntibodyCurated CorestaleIndapta Therapeutics, INC.Phase 3

Isatuximab (Isatuximab)

NHL; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#BioJungboMoa-pick#Popular+4
Trials 56Status Recruiting
AntibodyCurated CorestalePfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#BioJungboMoa-pick#Popular+4
Trials 54Status Recruiting
AntibodyLimited DatastalePfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 51Status Active
AntibodyLimited DatastaleJack Khouri, MDPhase 2

Siltuximab (Siltuximab)

Multiple Myeloma; Cytokine Release Syndrome · Myelofibrosis

#Myelofibrosis#Antibody#Phase2#monoclonal-antibody#MultipleMyeloma+3
Trials 43Status Recruiting
AntibodyLimited DatastaleRochePhase 3

Ocrelizumab, Rituximab, Ofatumumab (Anti-CD20 therapies, Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab))

Relapsing-Remitting Multiple Sclerosis (RRMS); Anti-CD20 Therapy · CD20

#CD20#Antibody#Phase3#monoclonal-antibody#Relapsing-RemittingMultipleScler+3
Trials 40Status Recruiting
AntibodyCurated CorestaleJanssenPhase 3

Talquetamab (Talquetamab)

Myeloma Multiple; Plasma Cell Leukemia · FRα

#FR#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+4
Trials 40Status Discontinued
AntibodyStandard DatabasestaleKyverna TherapeuticsPhase 2

Anti-CD20 mAB (Anti-CD20 mAB)

Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive · CD20

#CD20#Antibody#Phase2#monoclonal-antibody#MultipleSclerosis+3
Trials 31Status Recruiting
AntibodyLimited DatastaleGilead SciencesPhase 2

Magrolimab (Magrolimab)

Solid Tumor; Colorectal Cancer · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#monoclonal-antibody#SolidTumor+2
Trials 30Status Discontinued
AntibodyLimited DatastaleJanssenApproved

teclistamab OR talquetamab OR elranatamab OR linvoseltamab (teclistamab OR talquetamab OR elranatamab OR linvoseltamab)

Waldenstrom Macroglobulinaemia; Multiple Myeloma · Waldenstrom Macroglobulinaemia

#WaldenstromMacroglobulinaemia#Antibody#Approved#monoclonal-antibody#MultipleMyeloma+1
Trials 30Status Recruiting
AntibodyLimited DatastaleGenentech, Inc.Phase 3

Cevostamab (Cevostamab)

Relapsed or Refractory Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#monoclonal-antibody#RelapsedorRefractoryMultipleMyel+1
Trials 10Status Recruiting
AntibodyLimited DatastaleGlaxoSmithKlinePhase 2

Feladilimab (Feladilimab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#monoclonal-antibody#GlaxoSmithKline
Trials 9Status Recruiting
AntibodyLimited DatastaleJuno Therapeutics, Inc., a Bris…Phase 3

Alnuctamab (Alnuctamab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#monoclonal-antibody#Juno
Trials 5Status Discontinued

1 / 3 pages

← PreviousNext →